Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
Natera presented 17 abstracts at the ISHLT Annual Meeting, including six oral presentations, to highlight the expanding clinical utility of the Prospera test in heart and lung transplantation. Data from the ProTECT and DEFINE-HT studies demonstrated that Prospera predicted adverse outcomes up to 4x more often than biopsy and influenced physician decisions in over 30% of cases.
Key figures
- Oral presentations
- 6
- Abstracts presented
- 17
- False positive reduction
- 30%
- Reflux biomarker decrease
- 77%
- Clinical decision influence rate
- >30%
- Adverse outcome likelihood increase
- 4x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.